ArticleTransgenic research2003
Early parity significantly elevates mammary tumor incidence in MMTV-c-myc transgenic mice.
Article in Transgenic research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Female transgenic mice, in which a murine c-myc gene has been placed under the transcriptional control of the mouse mammary tumor virus long terminal repeat, are prone to developing mammary adenocarcinomas. Owing to the manner in which these mammary tumors develop, it is clear that exogenous expression of the c-myc transgene is necessary to but insufficient for murine mammary tumorigenesis. The genetic background of study mice has been shown to influence the phenotype induced by different transgenes; furthermore, mammary tumor initiation and progression induced by different transgenes has been shown to be susceptible to significant modification with alterations in and mixing of the genetic background of the study mice. We bred MMTV-c-myc transgenic mice onto a mixed genetic background that resulted in a very significant suppression of mammary tumor incidence for parous mice, bred continuously starting at 10 weeks of age. In this paper, we show that mammary tumor incidence is significantly elevated in these mixed background MMTV-c-myc transgenic mice when they are bred continuously, starting at 7 weeks of age. Early breeding of these mice did not influence mammary tumor multiplicity, latency, histopathology, or number of pregnancies at time of tumor development. These results are the first to demonstrate that breeding age influences mammary tumor incidence in MMTV-c-myc transgenic mice. They suggest that mammary gland susceptibility to tumorigenesis, resulting from the expression of c-myc, may vary with glandular development as is seen for chemical carcinogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.